Tobacco Harm Reduction (THR) involves adult smokers who would otherwise continue smoking moving down the risk continuum towards less risky*† products than traditional cigarettes.
Figure 1. Key THR science stakeholders and their position related to tobacco control
A growing body of global science supports the role of Smokeless Products, yet despite the tradition of harm reduction in public health, the regulatory and political landscape for THR remains complex (Figure 1). A big opportunity exists to bring scientific stakeholders together to unite and align in moving the public health strategy on tobacco forward.
Tobacco and nicotine product science has evolved rapidly in the past decade, driven by the diversification of the tobacco industry. In turn, this has driven an equally rapid evolution of tobacco and nicotine product science, conducted by those outside the industry. Through conducting this science, both industry and non-industry scientists are looking for answers to key questions related to THR. These questions can be grouped into five main categories (Figure 2) and include:
Figure 2. Summation of key questions from our analysis of U.S/EU/other regulatory bodies
Footnotes
* Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.
† Our Vapour product Vuse (including Alto, Solo, Ciro and Vibe), and certain products, including Velo, Grizzly, Kodiak, and Camel Snus, which are sold in the U.S., are subject to FDA regulation and no reduced-risk claims will be made as to these products without agency clearance.